The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
In Conversation
We recognize the value of the existing infrastructure and services provided by both the new GBACTI and the existing HKU-CTC. By working together, we can ensure…
Success in business requires more than just aggression—it requires strategy, understanding, and relentless dedication
We're about to inaugurate a new manufacturing unit for Halewood, which will be a state-of-the-art facility with international certifications like US FDA approval
We've strived for a culture rooted in fairness, transparency, and hard work
We recognize the substantial unmet medical needs in China and the growing potential of local innovation to drive global advancements
We are a global CDMO committed to delivering exceptional value and quality to our clients. Our extensive experience in meeting the stringent quality standards of global…
While we have already received approval for three products in China, our revenue aspirations extend beyond domestic markets
We have set an ambitious internal target where we aim for 50 percent of our value growth to stem from innovation by 2028 or 2030
As multinational companies, we must not only localize our operations but also recognize and leverage the unique strengths and perspectives of our Chinese counterparts
True biotech isn't about managing portfolios like big pharma does. It's about addressing unmet medical needs where there's a clinical void that larger pharmaceutical companies haven't…
The transition to annual updates [of China's National Reimbursement Drug List] has greatly enhanced patient access to innovative drugs, reflecting positive changes in the regulatory landscape
